Pharmacally
Health Tidings
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Health Tidings
Health TidingsAravax Reports Improved Peanut Tolerance with Monthly PVX108Aravax’s PVX108 met its primary endpoint in a Phase 2 peanut allergy trial, increasing maximum tolerated peanut dose 2.4-fold versus 1.2-fold with placebo.Fact-Checked
Health TidingsMerck Wins Positive EU CHMP Opinion for ENFLONSIA ExpansionMerck has secured a positive EU CHMP opinion recommending expanded use of ENFLONSIA (clesrovimab) to prevent RSV lower respiratory tract disease in high-risk children up to 24 months…Fact-Checked
Health TidingsNovo Nordisk Seeks FDA and EMA Approval for Etavopivat in Sickle Cell DiseaseNovo Nordisk has submitted etavopivat to the FDA and EMA for adolescents and adults with sickle cell disease.Fact-Checked
Health TidingsTaiho Completes Zipalertinib NDA After 6-Month PFS GainTaiho Oncology has completed its FDA NDA submission for zipalertinib plus platinum-based chemotherapy in first-line EGFR exon 20 insertion-positive NSCLC.Fact-Checked
Health TidingsGSK Secures Positive CHMP Opinion for Single-Dose Bexsero BoosterGSK’s Bexsero has received a positive CHMP opinion for a single-dose meningococcal B booster in individuals aged 10 years and older who were previously vaccinated at least two…Fact-Checked
Health TidingsKyverna Completes Miv-cel BLA, Deprioritizes KYV-102 ProgrammeKyverna Therapeutics has completed its rolling BLA submission for miv-cel in stiff person syndrome while deprioritizing KYV-102 to focus on advancing its late-stage neurological programmes.Fact-Checked
Health TidingsIntellia Reports 89% Reduction in HAE Attacks With Lonvo-zIntellia Therapeutics reports additional Phase 1/2 and Phase 3 findings for lonvoguran ziclumeran, showing an 89% reduction in HAE attacks, sustained biological activity and prophylaxis-free outcomes following a…Fact-Checked
Health TidingsNovartis Shows Durable Rhapsido Efficacy Across Three Urticaria SubtypesRhapsido (remibrutinib) demonstrates sustained 52-week efficacy across three chronic inducible urticaria subtypes in the Phase III RemIND study.Fact-Checked
Mergers & AcquisitionsAscidian Bets on Exegenesis to Optimize AAV Delivery for RNA Exon EditorsAscidian Therapeutics and Exegenesis Bio have partnered to combine RNA exon editing with AI-enabled AAV capsid discovery.Fact-Checked
Health TidingsImmunityBio Reports QUILT-2.005 Success for ANKTIVA Plus BCGImmunityBio announced that ANKTIVA plus BCG met the primary endpoint in the randomized QUILT-2.005 trial in BCG-naïve high-grade non-muscle invasive bladder cancer.Fact-Checked
Mergers & AcquisitionsPfizer Advances Berobenatide With $1.5B Blackstone DealPfizer has secured up to $1.5 billion in development funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP-1 receptor agonist for chronic weight management.Fact-Checked
Health TidingsJohnson & Johnson Reports Second Phase 3 Success for CAPLYTAJohnson & Johnson’s CAPLYTA met primary and key secondary endpoints in its second pivotal Phase 3 bipolar mania study.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.